Isis Pharmaceuticals Company Description
Isis Pharmaceuticals is trying to make sense out of antisense. The biotechnology company is developing drug therapies based on antisense technology, in which drugs attach themselves to strands of RNA in order to prevent them from producing disease-causing proteins; the hoped-for end result is a therapy that fights disease without harming healthy cells. Isis Pharmaceuticals works by discovering potential compounds (primarily in the areas of cardiovascular and metabolic disease but also in a range of other categories) and finding larger pharmaceutical partners to license the drugs or collaborate in their development. Its lead candidate is high cholesterol drug mipomersen, which Isis has licensed to Genzyme.
View the Comprehensive Company Description for Isis Pharmaceuticals
The Company Description provides a historical perspective of Isis Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Isis Pharmaceuticals's evolution in the marketplace.
